Trials / Completed
CompletedNCT01934231
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 Combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 3 Months – 15 Years
- Healthy volunteers
- Not accepted
Summary
Acute Bacterial Rhinosinusitis (ABRS) is a respiratory inflammation commonly seen in clinical practice, which has with respiratory symptoms including nasal congestion, rhinorrhoea, postnasal discharge and cough and is associated with headache, cheek pain, facial pressure and other conditions. The principal bacterial pathogens in causing ABRS include Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis. These three bacteria account for approximately 90% of ABRS in children less than or equal to 5 years of age. Combination of Potassium Clavulanate (CVA) and Amoxicillin (AMPC) produces higher antibiotic activity against beta-lactamase-producing bacteria. The present study is designed to assess the clinical efficacy, bacteriological efficacy and safety of CVA/AMPC (1:14) administered in children aged from 3 months to less than 15 years with ABRS. It is an open-label study consisting of a 7-day treatment phase and a post-treatment follow-up phase for 7 to 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amoxicillin-Potassium Clavulanate Combination | The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use. |
Timeline
- Start date
- 2013-08-30
- Primary completion
- 2013-11-07
- Completion
- 2013-11-07
- First posted
- 2013-09-04
- Last updated
- 2017-07-11
- Results posted
- 2014-07-01
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01934231. Inclusion in this directory is not an endorsement.